Charlotte Rees

911 total citations
9 papers, 306 citations indexed

About

Charlotte Rees is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Charlotte Rees has authored 9 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Surgery and 5 papers in Oncology. Recurrent topics in Charlotte Rees's work include Colorectal Cancer Treatments and Studies (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers) and Gastric Cancer Management and Outcomes (3 papers). Charlotte Rees is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers) and Gastric Cancer Management and Outcomes (3 papers). Charlotte Rees collaborates with scholars based in United Kingdom and United States. Charlotte Rees's co-authors include David Cunningham, Pippa Corrie, John Bridgewater, Justin S. Waters, Srinivasan Madhusudan, Sandy Beare, Daniel H. Palmer, Alison Backen, Harpreet Wasan and Juan W. Valle and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Charlotte Rees

8 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charlotte Rees United Kingdom	7	232	196	138	48	46	9	306
Joan Llach Spain	9	187 0.8×	184 0.9×	79 0.6×	36 0.8×	39 0.8×	20	306
Francesca Abbati Italy	8	208 0.9×	189 1.0×	128 0.9×	41 0.9×	67 1.5×	16	325
Ken Kato Japan	12	133 0.6×	187 1.0×	160 1.2×	30 0.6×	52 1.1×	42	341
Masanori Kotake Japan	11	174 0.8×	297 1.5×	117 0.8×	84 1.8×	56 1.2×	42	421
Luca Tondulli Italy	9	107 0.5×	174 0.9×	114 0.8×	36 0.8×	44 1.0×	14	285
Zhifan Zeng China	14	234 1.0×	371 1.9×	155 1.1×	41 0.9×	20 0.4×	36	443
S. Provent France	4	320 1.4×	220 1.1×	212 1.5×	30 0.6×	19 0.4×	7	365
Fernando Bonadeo Argentina	8	178 0.8×	251 1.3×	80 0.6×	38 0.8×	38 0.8×	10	302
Takeshi Kawakami Japan	8	118 0.5×	169 0.9×	190 1.4×	46 1.0×	41 0.9×	67	333
F. Daniel United Kingdom	8	144 0.6×	232 1.2×	174 1.3×	19 0.4×	71 1.5×	13	374

Countries citing papers authored by Charlotte Rees

Since Specialization

Citations

This map shows the geographic impact of Charlotte Rees's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlotte Rees with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlotte Rees more than expected).

Fields of papers citing papers by Charlotte Rees

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlotte Rees. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlotte Rees. The network helps show where Charlotte Rees may publish in the future.

Co-authorship network of co-authors of Charlotte Rees

This figure shows the co-authorship network connecting the top 25 collaborators of Charlotte Rees. A scholar is included among the top collaborators of Charlotte Rees based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlotte Rees. Charlotte Rees is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Patel, Bijal, Clare Peckitt, Katharina von Loga, et al.. (2021). Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.. Journal of Clinical Oncology. 39(15_suppl). 4015–4015. 7 indexed citations

Pucher, Philip H., Saqib Rahman, Robert Walker, et al.. (2020). Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. European Journal of Surgical Oncology. 46(12). 2248–2256. 19 indexed citations

Backen, Alison, Andre Lopes, Harpreet Wasan, et al.. (2018). Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer. 119(1). 27–35. 22 indexed citations

Saunders, Mark, James Paul, Gordon Brown, et al.. (2018). SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS.. Journal of Clinical Oncology. 36(4_suppl). 558–558.

Valle, Juan W., Harpreet Wasan, Andre Lopes, et al.. (2015). Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. The Lancet Oncology. 16(8). 967–978. 197 indexed citations

Valle, Juan W., Harpreet Wasan, Mark Jitlal, et al.. (2014). ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC).. Journal of Clinical Oncology. 32(15_suppl). 4002–4002. 4 indexed citations

Rees, Charlotte, Philip Beale, José Trigo, et al.. (2003). Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.. PubMed. 9(6). 2049–55. 11 indexed citations

Plummer, Ruth, Charlotte Rees, Andrew Hughes, et al.. (2003). A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.. PubMed. 9(4). 1313–22. 14 indexed citations

Ford, Hugo, David Cunningham, David Farrugia, et al.. (2002). Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.. PubMed. 8(1). 103–9. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact